CSL is under Algo Engine buy conditions and is a current holding in our ASX 100 model portfolio.
CSL & the Australian Government signed a Heads of Agreement to supply 51mn doses of the University of Queensland’s COVID-19 vaccine.
You're not a member! Trial today
CSL & AstraZeneca also signed a Heads of Agreement for manufacture & distribution of 30mn doses of AZN’s COVID-19 vaccine (AZD1222).
We expect EPS to increase by 8 – 10% in FY21 and FY22. This supports a forward dividend yield of 1.1%.
Buy CSL within the $265 – $280 support range.
